CSTONE PHARMA-B

2616
5.1550.96% ( -0.050 )
Delay Closed: Nov 16, 16:08:11

Overview

CSTONE PHARMA-B (2616)

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Main...

Open
5.110
High
5.230
Low
5.010
Prev. Close
5.205
Volume
5.26M
Turnover
27.10M
Avg Price
5.151
Bid/Ask Ratio
-61.70%
Amplitude
4.23%
52wk High
10.410
Volume Ratio
0.66
Turnover Ratio
0.33%
52wk Low
4.010
HK Mkt Cap
8.23B
Market CapHKD
8.23B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.302
EPSDynamic
-0.364
EPSStatic
--
BVPS
0.93
P/B
5.53
HK Shares
1.60B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.60B
Min lot size
500
Currency
HKD

CSTONE PHARMA-B Analyst Rating

View more

Forecast & Rating

Oct 29, 2026
Price forecast
HK$15.62203.09%
Forecast & RatingStrong buy
3analysts
  • Strong buy66.67%
  • Buy33.33%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    The stock dipped 0.96% to HK$5.155 today, primarily attributable to profit-taking following the recent Kimia Therapeutics clinical collaboration announcement. Q2 earnings released show operating revenue of HK$1.1845 billion, up 337.19% year-over-year, reflecting accelerating sales of flagship products including avelumab, pralsetinib, and sugemalimab; despite net loss of HK$145.7 million, the loss margin narrowed compared to the year-earlier period. The lead candidate CS2009 demonstrated 87.5% response rate in first-line PD-L1-high lung cancer with data from over 300 patients, supporting its mechanism and safety profile. The stock trades 50.48% below its 52-week high of HK$10.41 but has rebounded 28.55% from the June low of HK$4.01; year-to-date it has declined 3.46%; current price sits above the 20-day moving average but notably below the 60-day average. However, the company remains unprofitable with earnings power still requiring validation.

  2. Nov, 13

    Today's decline of approximately 4.8% to HKD 5.205 reflects profit-taking pressure following a series of positive catalysts, despite the company's revenue momentum. Key catalysts include: CS2009 data presented at ESMO 2026 conference demonstrating an impressive 87.5% response rate in first-line PD-L1-high lung cancer patients among 300+ study participants, coupled with a newly announced partnership with Kimia Therapeutics for solid-tumor drug development. While these milestones had previously driven share appreciation, investors are now realizing profits. On the earnings front, Q2 revenue climbed to HKD 118.4 million, representing substantial 337% year-over-year growth; however, the company remains in a loss-making phase with a net profit margin of -123%, typical for biotech firms in clinical-to-commercial transition. Regarding valuation, the stock has retreated 50% from its 52-week high of HKD 10.41, currently trading above its 20-day moving average of 5.09 but below the 60-day average of 5.46.

  3. Nov, 12

    CStone Pharma declined 0.27% to close at HKD 5.465, consolidating recent gains after multiple positive catalysts. The company recently announced a strategic collaboration with Kimia Therapeutics on solid-tumor drug development and disclosed clinical data from ESMO 2026 showing CS2009 achieved an impressive 87.5% response rate in first-line PD-L1-high lung cancer. These milestones drove a weekly gain of 7.98%. On the financial side, Q2 operating revenue surged to HKD 118.4 million, up 337% year-over-year, reflecting strong commercial momentum for its key products. However, the company remains unprofitable with a net loss of HKD 145.7 million and a net margin of −123%, indicating heavy R&D and commercialization costs. Regarding valuation, the stock is up 2.34% year-to-date but has retreated 47.5% from its 52-week high of HKD 10.41 reached in April, currently trading near the 60-day moving average of HKD 5.457. While the clinical progress and partnerships are encouraging, the ongoing losses and negative earnings multiple highlight execution risks that investors should monitor.

  4. Nov, 11

    CStone Pharmaceuticals closed flat at HK$5.48, after an intraday surge to HK$5.54 in morning trading before retreating. The early momentum was driven by positive sentiment from the recently-announced Kimia Therapeutics collaboration on solid-tumor drug development. Q2 2026 revenues reached HK$118.4 million, soaring 337% year-over-year, supported by sales of Apatinib (泰吉华) and Pralsetinib (普吉华), while pipeline asset CS2009 demonstrated an encouraging 87.5% response rate in first-line PD-L1-high lung cancer patients. The company posted a net loss of HK$145.7 million in the quarter, though the loss margin narrowed 1.57% year-on-year. From a valuation perspective, the stock remains 47.36% below its 52-week high of HK$10.41, with year-to-date gains of only 2.62%, indicating significant repricing from prior peaks despite recent positive catalysts.

  5. Nov, 10

    CStone Pharma advanced 1.29% to HKD 5.48 today, supported by recent clinical partnership announcements and robust trial data momentum. The company recently unveiled a solid-tumor drug development collaboration with Kimia Therapeutics, capitalizing on strong showings from its lead asset CS2009, which demonstrated an impressive 87.5% response rate in first-line PD-L1-high lung cancer patients. Year-to-date, the stock has accumulated a 2.62% gain from its lows, though it trades 47.36% below the 52-week high of HKD 10.41, suggesting persistent valuation pressure despite recent wins. On the earnings front, Q2 revenue surged 337.19% year-over-year to HKD 118.4 million, underscoring rapid commercialization execution, yet the company posted a substantial net loss of HKD 145.7 million with a net margin of -123%, indicating a protracted runway to profitability. With a market cap of approximately HKD 8.75 billion and a modest 0.32% turnover rate, CStone remains in an inflection phase where clinical validation must translate into financial sustainability.

News